{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T14:21:55Z","timestamp":1791037315624,"version":"4.1.0"},"reference-count":46,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2006,5,3]],"date-time":"2006-05-03T00:00:00Z","timestamp":1146614400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2006,6]]},"abstract":"<jats:p><jats:bold>Abstract:\u2002<\/jats:bold> We analyzed the expression of the inhibitor of apoptosis survivin by immunocytochemistry in bone marrow cells from patients with chronic myelomonocytic leukemia (CMML) to evaluate possible abnormalities in comparison with other myelodysplastic (MDS) and myeloproliferative syndromes, and to investigate a possible correlation between survivin expression and altered apoptosis or proliferation, or relevant laboratory and clinical findings. Thirty\u2010four patients with CMML [18 MDS\u2010CMML and 16 myeloproliferative disorder (MPD)\u2010CMML], 90 with MDS, 41 with acute myeloid leukemia (AML), 19 with chronic MPD and 25 control subjects were studied. In normal samples survivin was never detectable. In CMML survivin levels higher than in MDS and AML (<jats:italic>P<\/jats:italic>\u2003&lt;\u20030.0001), but similar to those found in MPD were observed. In CMML and MDS apoptosis was significantly higher compared to normal controls and all other subtypes of leukemias (<jats:italic>P<\/jats:italic>\u2003&lt;\u20030.0001). Proliferation did not differ significantly in normal controls, MDS and CMML; the lowest levels were observed in AML and MPD (<jats:italic>P<\/jats:italic>\u2003&lt;\u20030.0001). In CMML there was no correlation between survivin expression and blast cell percentage, apoptosis or proliferation, FAB or WHO subgroup. Proliferation was higher in MDS\u2010CMML and tended to correlate with overall survival. CMML\u20102 cases with higher survivin expression showed higher evolution rate and shorter survival. In conclusion, CMML is characterized by high proliferation and apoptosis. Survivin overexpression, by disrupting the balance between cell proliferation\/differentiation and apoptosis, may play an important role in its pathophysiology. The detection of survivin\u2010deregulated expression may provide a useful tool for diagnosis, prognosis and a possible target for experimental treatments.<\/jats:p>","DOI":"10.1111\/j.0902-4441.2006.t01-1-ejh2588.x","type":"journal-article","created":{"date-parts":[[2006,3,9]],"date-time":"2006-03-09T16:22:40Z","timestamp":1141921360000},"page":"494-501","source":"Crossref","is-referenced-by-count":16,"title":["Survivin expression, apoptosis and proliferation in chronic myelomonocytic leukemia"],"prefix":"10.1111","volume":"76","author":[{"given":"Rosangela","family":"Invernizzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Travaglino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Benatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Malcovati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo Della","family":"Porta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Cazzola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo","family":"Ascari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2006,5,3]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm0897-917"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.273.18.11177"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/25141"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.20140"},{"key":"e_1_2_6_6_2","first-page":"5315","article-title":"IAP\u2010family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs","volume":"58","author":"Tamm I","year":"1998","journal-title":"Cancer Res"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1206509"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2004.08.149"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)13910-4"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI200422222"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/70487"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)70294-4"},{"key":"e_1_2_6_13_2","first-page":"127","article-title":"Expression of survivin and its relationship to loss of apoptosis in breast carcinomas","volume":"6","author":"Tanaka K","year":"2000","journal-title":"Clin Cancer Res"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.9.2784"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2000.02328.x"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0145-2126(00)00065-5"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.9.2777"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1080\/1042819021000039956"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.thj.6200549"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428190412331283251"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-8588(03)00086-8"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1994.tb06734.x"},{"key":"e_1_2_6_23_2","volume-title":"World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues","author":"Jaffe ES","year":"2001"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1177\/44.9.8773561"},{"key":"e_1_2_6_25_2","first-page":"202","article-title":"CMML: a biologically distinct myeloproliferative disease","volume":"2","author":"Cortes J","year":"2003","journal-title":"Curr Hematol Rep"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0145-2126(97)00192-6"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.6.2079"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0145-2126(02)00021-8"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.3.840"},{"key":"e_1_2_6_30_2","first-page":"866","article-title":"Prognostic factors in myelodysplastic and myeloproliferative types of chronic myelomonocytic leukemia: a retrospective analysis of 83 patients from a single institution","volume":"89","author":"Breccia M","year":"2004","journal-title":"Haematologica"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1080\/1042819042000207271"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0145-2126(01)00170-9"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-07-2761"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2004.10.034"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2004.03.020"},{"key":"e_1_2_6_36_2","first-page":"589","article-title":"Expression of the antiapoptotic gene survivin in chronic myeloid leukemia","volume":"23","author":"Badran A","year":"2003","journal-title":"Anticancer Res"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428190500052131"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm750"},{"key":"e_1_2_6_39_2","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1182\/blood.V71.6.1707.1707","article-title":"Mutation of Ki\u2010ras and N\u2010ras oncogenes in myelodysplastic syndromes","volume":"71","author":"Lyons J","year":"1988","journal-title":"Blood"},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-04-1150"},{"key":"e_1_2_6_41_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-05-1898"},{"key":"e_1_2_6_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0037-1963(03)70046-8"},{"key":"e_1_2_6_43_2","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1281.019"},{"key":"e_1_2_6_44_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.170.11.5391"},{"key":"e_1_2_6_45_2","first-page":"2683","article-title":"Therapeutic targeting of the survivin pathway in cancer: initiation of mitochondrial apoptosis and suppression of tumor\u2010associated angiogenesis","volume":"9","author":"Blanc\u2010Brude OP","year":"2003","journal-title":"Clin Cancer Res"},{"key":"e_1_2_6_46_2","doi-asserted-by":"publisher","DOI":"10.1023\/B:APPT.0000045788.61012.b2"},{"key":"e_1_2_6_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2004.08.007"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.0902-4441.2006.t01-1-EJH2588.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.0902-4441.2006.t01-1-EJH2588.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T03:08:21Z","timestamp":1696993701000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.0902-4441.2006.t01-1-EJH2588.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,5,3]]},"references-count":46,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2006,6]]}},"alternative-id":["10.1111\/j.0902-4441.2006.t01-1-EJH2588.x"],"URL":"https:\/\/doi.org\/10.1111\/j.0902-4441.2006.t01-1-ejh2588.x","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,5,3]]}}}